Letrozol Sandoz

Letrozole, the active ingredient in Letrozol Sandoz, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of hormone receptor‑positive breast cancer in postmenopausal women, reducing estrogen production that can stimulate tumor growth.

GNH USA supplies Letrozol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable sourcing for hospitals, pharmacies and clinical trial sites, ensuring timely delivery through regulated distribution channels.

Letrozol Sandoz, an aromatase inhibitor, is indicated for conditions driven by estrogen signaling in breast cancer.

- Hormone receptor‑positive breast cancer (postmenopausal): reduces tumor progression by lowering systemic estrogen levels. - Adjuvant therapy for early‑stage breast cancer (postmenopausal): decreases risk of disease recurrence after surgery. - Metastatic breast cancer (postmenopausal): helps control disease spread by suppressing estrogen‑dependent tumor growth.

Letrozol Sandoz may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Bone fracture: increased risk due to decreased estrogen. - Pulmonary embolism: sudden shortness of breath, chest pain. - Myocardial infarction: heart attack symptoms. - Anaphylaxis: severe allergic reaction with rash, swelling. - QT prolongation: cardiac rhythm disturbance.

When prescribing Letrozol Sandoz, clinicians should observe several precautionary measures to ensure patient safety. - Bone health assessment: evaluate baseline bone mineral density and consider calcium/vitamin D supplementation. - Liver function monitoring: check hepatic enzymes before initiation and periodically during therapy. - Cardiovascular risk evaluation: assess history of thromboembolic events or heart disease. - Avoid use in premenopausal women: drug is ineffective and may cause ovarian stimulation. - Review concomitant medications: identify potential drug interactions that may alter letrozole levels. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Letrozol Sandoz can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce letrozole plasma concentrations. - Estrogen‑containing hormonal therapies (e.g., combined oral contraceptives): counteract the drug’s estrogen‑lowering effect. - Tamoxifen: antagonistic action may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole, omeprazole): may increase letrozole exposure. - Anticoagulants (e.g., warfarin): potential alteration of INR, requiring closer monitoring. - SSRIs (e.g., fluoxetine): possible additive effect on fatigue and mood changes.